BioTech Breakthrough Acknowledges Champions Oncology Innovation with the "Contract Research and Development Innovation Award"
Key Highlights
- ➤Champions Oncology receives BioTech Breakthrough’s Contract Research and Development Innovation Award
- ➤Cell surface proteomics measures surface and intracellular proteins directly from metastatic patient-derived tumors
- ➤Patient-matched multi-omics links surface proteins with genetic drivers, drug sensitivity, and resistance patterns
- ➤BioTech Breakthrough calls the dataset the most clinically relevant cell surface proteomics dataset globally
Expert Statements
Rob Brainin, CEO of Champions Oncology
“Conventional surfaceome approaches can miss the biology that determines whether a target is truly surface-accessible, clinically relevant, and likely to translate to patients. We operate at the intersection of translational oncology and drug discovery, and what makes our surfaceome data actionable is not simply its scale. It is that every protein we identify and measure on a tumor's surface is linked to the clinical history and in vivo drug response of the model it came from. That connection is what turns a list of surface proteins into decisions about which target to pursue.”
Rob Brainin, CEO of Champions Oncology
“We're proud to accept the ‘Contract Research and Development Innovation Award’ from BioTech Breakthrough.”
Bryan Vaughn, Managing Director, BioTech Breakthrough
“Champions Oncology is redefining how drug developers identify and validate cell-surface targets. Most surfaceome datasets depend on imperfect proxies: immortalized cell lines or RNA-expression inference. Cell lines lose the tumor heterogeneity and native biology that make surface expression clinically meaningful in the first place. Mistargeting a protein that is not surface-accessible wastes years of development.”
Bryan Vaughn, Managing Director, BioTech Breakthrough
“By building from relapsed and metastatic patient tumors and preserving that biology through to the proteomic readout, Champions Oncology has assembled the most clinically relevant cell surface proteomics dataset available globally, one where a target's surface expression can be traced back to the patient response and resistance biology it came from.”
HACKENSACK, NJ / ACCESS Newswire / November 10, 2026 / Champions Oncology, Inc., a leader in translational oncology research solutions powered by clinically annotated patient-derived models and proprietary multi-omic datasets, today announced it is the recipient of the "Contract Research and Development Innovation Award" in the sixth annual BioTech Breakthrough Awards program conducted by BioTech Breakthrough, an independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products and services around the globe.
The award recognizes Champions' cell surface proteomics platform, which addresses a long-standing challenge in target discovery: most surfaceome data comes from cell lines or RNA inference rather than direct protein measurement in clinically relevant tumors. Champions generates its cell surface proteomics dataset directly from advanced-stage, metastatic tumors in its living patient-derived tumor bank, using a proprietary workflow that isolates plasma membranes from the rest of the cell. Surface and intracellular protein fractions are quantified in parallel, enabling researchers to see true surfaceome enrichment, while paired ultra-high-depth whole cell proteomics provide maximum analytical flexibility.
Get started
Create a free account to read the full story.